Initially, it was listed in recommendations as an option only in patients with inadequate response to tumor necrosis factor (TNF) inhibitors [7], but it has subsequently been recommended as one of the first line bDMARDs for RA [8]. The gene discussed is TNF; the disease is rheumatoid arthritis.